SARASOTA, Fla., Sept. 28, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.:
Sciax Corp. (Pink Sheets:SCXC), Pharmacopeia Drug Discovery, Inc. (Nasdaq:PCOP) Neurocrine Biosciences, Inc. (Nasdaq:NBIX) and Radiation Therapy Services Inc. (Nasdaq:RTSX).
Sciax Corp. (Pink Sheets:SCXC), an emerging leader in defense imaging systems for law enforcement and military personnel, engaged in counter-terrorism and other special security operations, reported on Monday after the closing bell on two more sales to BP Canada, a large oil and gas industry customer, for endoscope equipment used in the visual inspection of large reciprocating engines.
"We intend to pursue sales opportunities in the oil and gas industry on an expanding basis and our long term partnership with Richard Wolf is a very important component of our strategy," stated Ralph Manore, Vice President of Operations for Sciax.
News on the Nasdaq;
Neurocrine Biosciences, Inc. (Nasdaq:NBIX) -- Pharmacopeia Drug Discovery, Inc. (Nasdaq:PCOP)
Collaborative drug discovery company Pharmacopeia Drug Discovery, Inc. (Nasdaq:PCOP) announced after the closing bell Monday that a research milestone has been reached in its collaboration with Neurocrine Biosciences, Inc. (Nasdaq:NBIX).
Pharmacopeia Drug Discovery said that the milestone payment was triggered by Neurocrine's acceptance of the compounds delivered by Pharmacopeia in the lead discovery phase of the collaboration. The company, which is entitled to additional pre-clinical and clinical development milestone payments as this program progresses towards the market, did not comment on the exact amount of the milestone payment, and added that the company is further entitled to royalties on commercial sales of any products resulting from this collaboration.
Shares of PCOP closed Monday's regular trading session at $4.76, up $0.04 or 0.85 percent, on a volume of 54K shares. NBIX shares closed at $46.44, down $1.65 or 3.43 percent, on a volume of 424K shares.
Radiation Therapy Services Inc. (Nasdaq:RTSX)
Radiation therapy centers operator Radiation Therapy Services Inc. announced Monday after the bell that there is no business disruption due to Hurricane Jeanne, which hit Florida on September 26. All the centers on the east and west coasts of Florida and on the Panhandle are open and operating, the company said.
Daniel Dosoretz, President and CEO, said, "Hurricane Jeanne is the fourth hurricane to hit Florida in the last six weeks. Our 24 centers across the state experienced no impact from this storm."
Shares of RTSX closed Monday's regular trading session at $12.25
About eLocity Inc: eLocity owns and operates three financial websites for investors.
-PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
-StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.
-Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, here after referred to as "the company". The company is expected to receive compensation for this newsletter service for Sciax Corp. (public company). The compensation is fifteen thousand dollars from a non-affiliated third party, Alex Consulting Inc. Because the company is receiving compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the public company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.